Form 4: United Therapeutics Insider Trades 06/23/2026

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported significant stock transactions on June 23, 2026, involving option exercises and stock sales under a 10b5-1 plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO and Director of United Therapeutics Corp, engaged in a series of stock transactions on June 23, 2026.
• These transactions included the exercise of stock options and the subsequent sale of common stock.
• The exercise of stock options occurred at a price of $135.42 per share, resulting in the acquisition of 9,500 shares.
• A total of 299 to 3,407 shares were sold in multiple transactions throughout the day, with weighted average prices ranging from $539.62 to $546.55.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• The 10b5-1 plan is set to continue until the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026, whichever comes first.
• Following these transactions, Rothblatt's direct beneficial ownership of common stock is 49,714 shares.
• Indirect beneficial ownership includes holdings through various trusts and by a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; while it details significant insider selling, it was conducted under a pre-arranged 10b5-1 plan, mitigating immediate negative sentiment.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive sales.
• The exercise of stock options at $135.42 suggests a significant gain compared to the sale prices.
• The reporting person continues to hold a substantial number of shares indirectly through trusts and by spouse.

Negatives

• A significant number of shares were sold by a key executive, which could be interpreted negatively by the market.
• The weighted average sale price of approximately $540-$546 indicates a substantial value realized from the sales.

Risks

• The ongoing 10b5-1 plan allows for continued sales of stock, which could put downward pressure on the stock price if executed in large volumes.
• The expiration of stock options on March 15, 2027, may influence the timing and volume of future transactions under the plan.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. This indicates potential for further stock transactions by the reporting person.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives managing their compensation and diversification. The significant difference between the option exercise price and the sale price highlights the value creation for executives.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, although the 10b5-1 plan provides context.
• Management: Demonstrates a strategy for managing equity compensation and diversification.

Next Steps

• Continue to monitor transactions under the 10b5-1 plan until its termination date or option exercise limit.
• Observe the company's stock performance in light of ongoing insider selling.

Key Dates

Recommendation

The filing details routine insider transactions under a 10b5-1 plan, which are generally not indicative of a change in fundamental outlook for the company. While significant selling can create short-term price pressure, the pre-planned nature suggests it's for personal financial management rather than a negative view of the company's prospects. Therefore, a 'hold' recommendation is appropriate pending further fundamental analysis.

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Martine Rothblatt, Beneficial Ownership, SEC Filing